Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 4/20 | 0.46 |
| ▸ | INPP5A | Q14642 | 4/20 | 0.46 |
| ▸ | INPP5B | P32019 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11253571 | 0.89 | CA1 (0.52) | ALDH1A1SRCKDM4EHPGDHSD17B10 | |
| SCHEMBL9492467 | 0.87 | SMN1; SMN2 (0.62) | INPPL1INPP5AINPP5BALDH1A1SRC | |
| SCHEMBL8639179 | 0.87 | GAA (0.53) | INPPL1INPP5AINPP5BALDH1A1SRC | |
| SCHEMBL8519276 | 0.85 | LMNA (0.46) | INPPL1INPP5AINPP5BALDH1A1SRC | |
| SCHEMBL9058386 | 0.85 | INPPL1 (0.39) | INPPL1INPP5AINPP5BALDH1A1SRC | |
| SCHEMBL29070724 | 0.85 | KDM4E (0.45) | INPPL1INPP5AINPP5BALDH1A1SRC | |
| SCHEMBL1027274 | 0.82 | HTT (0.48) | INPPL1INPP5AINPP5BALDH1A1KDM4E | |
| SCHEMBL5852168 | 0.82 | L3MBTL1 (0.44) | INPPL1INPP5AINPP5BALDH1A1SRC | |
| SCHEMBL3116257 | 0.82 | GPR84 (0.51) | ALDH1A1SRCKDM4EUSP2HPGD | |
| SCHEMBL9949532 | 0.80 | TDP1 (0.44) | INPPL1INPP5AINPP5BALDH1A1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834130-B2 | Process for the production of polybenzimidazole from a tetraminobiphenyl and an isophthalic acid | PBI PERFORMANCE PRODUCTS, INC. (US) | 2010-11-16 | — | — | US | claimed |
| US-20080207869-A1 | PROCESS FOR THE PRODUCTION OF POLYBENZIMIDAZOLE FROM A TETRAMINOBIPHENYL AND AN ISOPHTHALIC ACID | PBI PERFORMANCE PRODUCTS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008103604-A2 | PROCESS FOR THE PRODUCTION OF POLYBENZIMIDAZOLE FROM A TETRAMINOBIPHENYL AND AN ISOPHTHALIC ACID | PBI PERFORMANCE PRODUCTS, INC. (US) | 2008-08-28 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0036077-B1 | ESTERS OF HYDROXYLALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITION CONTAINING THESE ESTERS AS ACTIVE INGREDIENTS | Newport Pharmaceuticals International, Inc. (US) | 1984-08-15 | — | — | EP | claimed |
| EP-0012397-B1 | POLYMERIZATION CATALYST AND PROCESS FOR POLYMERIZING ALPHA-OLEFINS | PHILLIPS PETROLEUM COMPANY (US) | 1984-02-15 | — | — | EP | claimed |
| EP-0036077-A2 | Esters of hydroxylalkyl-purines, processes for preparing them and therapeutical composition containing these esters as active ingredients | Newport Pharmaceuticals International, Inc. (US) | 1981-09-23 | — | — | EP | claimed |
| US-20250368598-A1 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | BHATTACHARYA SHRABANTI (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4543841-A2 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | The University of North Carolina at Chapel Hill (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2023250180-A2 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-0087326-A1 | Substituted pyrimidin-2-ones and the salts thereof | NYCOMED AS (NO) | 1983-08-31 | — | — | EP | disclosed |
| EP-0074611-A2 | Method for production of cephalosporin compounds | Takeda Chemical Industries, Ltd. (JP) | 1983-03-23 | — | — | EP | disclosed |
| US-4340726-A | PURINE COMPOUNDS HAVING IMMUNOMODULATOR, ANTIVIRAL ANTITUMOR AND ENZYME INHIBITOR ALTIVITY | NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 1982-07-20 | — | — | US | disclosed |
| EP-0036077-A2 | Esters of hydroxylalkyl-purines, processes for preparing them and therapeutical composition containing these esters as active ingredients | Newport Pharmaceuticals International, Inc. (US) | 1981-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368598-A1 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | CA4, CA12, CA14 | INPPL1 1810/4885INPP5A 1195/4885INPP5B 809/4885 |
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | PAICS, COASY, CDS2 | INPPL1 55/4885INPP5A 280/4885INPP5B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.